UPDATES IN MEDICINE

2021-08-31 05:43:10 ​​ EMPEROR-Preserved: A new hope for Heart Failure with Preserved Ejection Fraction

● CONCLUSIONS - Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.


Join @Updates_in_Medicine Open / Comment

2021-08-29 18:08:08 ​​ Finerenone reduces Cardiovascular Events in Diabetic CKD Patients (FIGARO-DKD Trial)

In this double-blind trial, patients with stage 1 to 4 chronic kidney disease and type 2 diabetes were randomly assigned to receive finerenone or placebo. Finerenone treatment was superior with regard to the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-08-28 12:13:05 @Updates_in_Medicine Open / Comment

2021-08-28 11:51:43 ​​ A Monoclonal Antibody for Malaria Prevention

Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. 


Join @Updates_in_Medicine


●https://www.nejm.org/doi/full/10.1056/NEJMoa2034031 Open / Comment

2021-08-26 05:19:14 @Updates_in_Medicine Open / Comment

2021-08-26 04:06:44 ​​ ANTICOAGULATION IN COVID 19
(The REMAP-CAP, ACTIV-4a, and ATTACC Investigators)

Anticoagulation in Critically Ill Patients with Covid-19

In a randomized trial, patients with severe Covid-19 were assigned to receive either therapeutic-dose anticoagulation or usual-care pharmacologic throm­bo­pro­phy­laxis. At 21 days, therapeutic-dose anticoagulation did not improve hospital survival or the number of days free of cardiovascular or respiratory organ support.


Anticoagulation in Moderate Covid-19

In a randomized trial, patients with moderately severe Covid-19 were assigned to receive either therapeutic-dose anticoagulation or usual-care throm­bo­pro­phy­laxis. At 21 days, therapeutic-dose anticoagulation resulted in a higher probability of survival until hospital discharge without organ support.



● Join @Updates_in_Medicine

● Click the links below to read full articles Open / Comment

2021-08-24 05:05:43 ​​ What is SUBACUTE COVID 19 & POST COVID 19 SYNDROME

● ACUTE COVID-19: signs and symptoms of COVID-19 for up to 4 weeks.

● SUBACUTE COVID-19: signs and symptoms of COVID-19 from 4 to 12 weeks.

● Post-COVID-19 syndrome: signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis


Join @Updates_in_Medicine
. Open / Comment

2021-08-23 04:49:59 ​​ Convalescent Plasma for High-Risk Covid-19

Patients who were seen in emergency departments within 7 days after the onset of Covid-19 symptoms and were considered appropriate for discharge were randomly assigned to receive either convalescent plasma or placebo. Convalescent plasma did not prevent disease progression.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-08-18 04:28:18 ​​ Vaccine Effectiveness against Delta Covid-19 Variant

The B.1.617.2 (delta) Covid-19 variant has surged in India and spread worldwide. In a test-negative case–control study, the effectiveness of two doses of BNT162b2 (Pfizer) was 94% against the B.1.1.7 (alpha) variant and 88% against delta; with the ChAdOx1 nCoV-19 (AstraZeneca) vaccine, effectiveness was 74% and 67%, respectively. Protection after a single vaccine injection was low; two doses are needed.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-08-12 04:28:52 ​​ Moderna Vaccine in Adolescents

In a trial of mRNA-1273 or placebo involving 3700 adolescents 12 to 17 years of age, two doses of vaccine stimulated high levels of neutralizing antibodies, with a side-effect profile similar to that seen in other age groups. The incidence of Covid-19 in the unvaccinated group was too low to gauge protection, but Covid-19 did not develop in any vaccinated participants.


Join @Updates_in_Medicine
@The_NEJM Open / Comment